Two Sigma Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

Two Sigma Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,855	Closed	-$818K	–	2856
2021 Q4	$818K	Sell	18,855 -18,180	-49%	-$1.05M	﹤0.01%	1666
2021 Q3	$2.64M	Buy	37,035 +3,965	+12%	+$364K	0.01%	1101
2021 Q2	$3.8M	Buy	33,070 +5,610	+20%	+$548K	0.01%	989
2021 Q1	$2.85M	Buy	+27,460	New	+$2.61M	0.01%	1102
2020 Q3	–	Sell	-2,155	Closed	-$82K	–	2570
2020 Q2	$82K	Buy	+2,155	New	+$111K	﹤0.01%	2383

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Advisers's IMDX Position: Q1 2022 in Review

Two Sigma Advisers sold out of Insight Molecular Diagnostics (IMDX) in Q1 2022, closing a stake of 18,855 shares — an estimated $818K sold.

Two Sigma Advisers first reported a position in IMDX in Q2 2020 and held it in 5 quarters. The position peaked at $3.8M in Q2 2021. 86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

Two Sigma Advisers reported no remaining Insight Molecular Diagnostics position as of Q1 2022 after selling out during the quarter.
Two Sigma Advisers sold 18,855 Insight Molecular Diagnostics shares in Q1 2022, an estimated $818K.
Two Sigma Advisers first reported a position in Insight Molecular Diagnostics in Q2 2020 and held it in 5 quarters.
Two Sigma Advisers's Insight Molecular Diagnostics position peaked at $3.8M in Q2 2021.
86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.